Fact based stock research
Bio-Rad Laboratories (NYSE:BIO)
US0905722072
Bio-Rad Laboratories stock research in summary
Bio-Rad Laboratories shares have a market-typical stock price level. They are good value, are safely financed and show above average growth. We recommend evaluating whether the future of the company Bio-Rad Laboratories is typical for this industry which the market average price level of the shares suggests. If you believe that the future of the company is above average, that could be an argument for buying the shares and vice versa.
Latest Obermatt Ranks
Value Rank | 62 | ![]() |
Growth Rank | 54 | ![]() |
Safety Rank | 61 | ![]() |
Combined Rank | 64 | ![]() |
January 8, 2021. Stock data may be delayed. Login to get the most recent research.
Google: Bio-Rad Laboratories
Research History: Bio-Rad Laboratories
RESEARCH HISTORY | 2018 | 2019 | 2020 | 2021 | ||||
---|---|---|---|---|---|---|---|---|
VALUE | ||||||||
VALUE | 71 |
![]() |
58 |
![]() |
62 |
![]() |
62 |
![]() |
GROWTH | ||||||||
GROWTH | 38 |
![]() |
53 |
![]() |
54 |
![]() |
54 |
![]() |
SAFETY | ||||||||
SAFETY | 94 |
![]() |
94 |
![]() |
61 |
![]() |
61 |
![]() |
COMBINED | ||||||||
COMBINED | 88 |
![]() |
82 |
![]() |
64 |
![]() |
64 |
![]() |
Value Metrics in Detail
VALUE METRICS | 2018 | 2019 | 2020 | 2021 | ||||
---|---|---|---|---|---|---|---|---|
PRICE VS. REVENUES (P/S) | ||||||||
PRICE VS. REVENUES (P/S) | 59 |
![]() |
42 |
![]() |
46 |
![]() |
46 |
![]() |
PRICE VS. PROFITS (P/E) | ||||||||
PRICE VS. PROFITS (P/E) | 100 |
![]() |
98 |
![]() |
100 |
![]() |
100 |
![]() |
PRICE VS. CAPITAL (Market-to-Book) | ||||||||
PRICE VS. CAPITAL (Market-to-Book) | 62 |
![]() |
56 |
![]() |
63 |
![]() |
63 |
![]() |
DIVIDEND YIELD | ||||||||
DIVIDEND YIELD | 1 |
![]() |
1 |
![]() |
1 |
![]() |
1 |
![]() |
CONSOLIDATED RANK: VALUE | ||||||||
CONSOLIDATED RANK: VALUE | 71 |
![]() |
58 |
![]() |
62 |
![]() |
62 |
![]() |
Growth Metrics in Detail
GROWTH METRICS | 2018 | 2019 | 2020 | 2021 | ||||
---|---|---|---|---|---|---|---|---|
REVENUE GROWTH | ||||||||
REVENUE GROWTH | 13 |
![]() |
25 |
![]() |
37 |
![]() |
37 |
![]() |
PROFIT GROWTH | ||||||||
PROFIT GROWTH | 33 |
![]() |
47 |
![]() |
43 |
![]() |
43 |
![]() |
STOCK RETURNS | ||||||||
STOCK RETURNS | 86 |
![]() |
69 |
![]() |
70 |
![]() |
70 |
![]() |
CONSOLIDATED RANK: GROWTH | ||||||||
CONSOLIDATED RANK: GROWTH | 38 |
![]() |
53 |
![]() |
54 |
![]() |
54 |
![]() |
Safety Metrics in Detail
SAFETY METRICS | 2018 | 2019 | 2020 | 2021 | ||||
---|---|---|---|---|---|---|---|---|
LEVERAGE | ||||||||
LEVERAGE | 56 |
![]() |
50 |
![]() |
35 |
![]() |
35 |
![]() |
REFINANCING | ||||||||
REFINANCING | 74 |
![]() |
62 |
![]() |
71 |
![]() |
71 |
![]() |
LIQUIDITY | ||||||||
LIQUIDITY | 81 |
![]() |
94 |
![]() |
68 |
![]() |
68 |
![]() |
CONSOLIDATED RANK: SAFETY | ||||||||
CONSOLIDATED RANK: SAFETY | 94 |
![]() |
94 |
![]() |
61 |
![]() |
61 |
![]() |
Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Bio-Rad Laboratories from January 8, 2021.
We invest in our stock tips ourselves and openly publish the returns of our portfolio. That's how much we believe in our stock research. Subscribe to the top 10 stocks for 100 markets conveniently by e-mail.